AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
CARAvis Budget Group(CAR) Seeking Alpha·2024-11-21 13:16

Autolus Therapeutics plc (NASDAQ: AUTL ) is a promising CAR T-cell biotech that recently received FDA approval for AUCATZYL. This is AUTL's main value driver, and it's indicated for relapsed or refractory B-cell precursor acute lymphoblastic leukemia [ALL]. Based onMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate ...